Navigation Links
A protein in the brain paves way for Alzheimer's treatment

Alzheimer's is the most common form of dementia in Canada, affecting some 5% of people over the age of 65. Statistics show that one in four people// over the age of 85 suffer from the disease. According to the study conducted by Dr. Peter St George-Hyslop who is a researcher working on Alzheimer's disease at the University of Toronto it is said that a single chemical in the brain is the cause of the disease. The researchers have discovered a substance in the brain that can stop Alzheimer's disease and could lead to a treatment for the degenerative disorder.

By using this discovery a new drug can be developed against the disease. Medicines that will stop the progressing of the disease and also those that will help to prevent the occurrence of the disease would soon be discovered. TPM21 is the protein that blocks the neurotoxin Abeta. This is known as beta-amyloid peptide, which is responsible for the onset of Alzheimer's. TPM21 blocks Abeta production without causing any side effects. But St George-Hyslop also cautioned that it has yet to be tested in animals and that a drug to mimic its antitoxin effects is likely at least five years away.

The crucial point is now to discover a small molecule that resembles and functions in the same way as this protein. Abeta-blocking compound would likely be used in conjunction with other therapies, such as a promising new Alzheimer's vaccine. Alzheimer's drug therapy would also require ongoing doses over a patient's lifetime. Dr. B. Lynn Beattie, chair of the research policy committee for the Alzheimer Society of Canada, cautioned that the disease has an enormously complex biochemistry and that this newly revealed protein represents just one step in the development of the disease.


'"/>




Page: 1

Related medicine news :

1. Special proteins to fight TB identified
2. High-protein diets may pose health risks
3. Hidden influenza virus protein found
4. Special proteins to fight TB identified
5. Importance of soy protein in your diet
6. Unfavourable Lipid-Lipoprotein profiles in older adults has been linked to abdominal visceral fat
7. Stroke victims have new hope with activated protein C
8. Mental retardation linked to brain protein
9. HIV blocking protein in Monkey
10. Obese children may have abnormalities of lipoproteins
11. Artificially made protein to inhibit angiogenesis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/22/2017)... , ... February 22, 2017 , ... A product of ... seem to derive a heart-protective benefit from eating soy foods, while others do not, ... men who are able to produce equol—a substance made by some types of “good” ...
(Date:2/22/2017)... ... February 22, 2017 , ... Forty-five percent ... those report that family members or friends have also commented about their poor ... loss wear hearing aids. One reason, suggested by 89 percent of American respondents, ...
(Date:2/22/2017)... , ... February 22, 2017 , ... Super-Sod will attend ... 26 event in Athens, Georgia. , A shift from Super-Sod’s simple Athens Home Show ... , For the booth, grass seed plant manager Chris Roquemore constructed furniture from recycled ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... Social media ... especially for hospitals and health systems. Smith & Jones’ delves into this insight and ... episode, President of Smith & Jones David Vener meets up with social media strategist ...
(Date:2/22/2017)... ... February 22, 2017 , ... BrightStar Care Charleston , a ... Medical University of South Carolina (MUSC) Center on Aging’s Senior Expo on Thursday, ... on Aging is a tremendous resource in our community. We are thrilled to participate ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... 2017 Research and Markets has announced ... (Thermometers - Digital, Infrared, Mercury; Trend Indicator):Analysis By Region, By Country ... ... forecasted to grow at a CAGR of 5.33% during 2016-2021 ... infectious diseases along with surging demand of digital thermometer. Apart from ...
(Date:2/22/2017)... Feb. 22, 2017 Oncternal Therapeutics, Inc., ... both rare and common malignancies, today announced the ... The company intends to use the proceeds to ... and to advance preclinical development of a new ... is a first-in-class anti-ROR1 monoclonal antibody being developed ...
(Date:2/22/2017)... -- Kineta, Inc., a biotechnology company focused on ... today announced that KCP-400 (RgIA4), a potent antagonist ... robust chronic pain relief and disease modifying effects ... the a9a10 nAChR as a new, non-opioid target ... were reported online in the February 20 th ...
Breaking Medicine Technology: